日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer

Claudin 18.2 表达对 HER2 阳性胃癌或胃食管交界处癌患者曲妥珠单抗疗效的影响

Okemoto, D; Nakayama, I; Jubashi, A; Sakamoto, N; Okunaka, M; Matsubara, Y; Miyashita, Y; Kobayashi, A; Okazaki, U; Yamamoto, K; Seguchi, K; Hosokai, T; Ogura, T; Mishima, S; Kotani, D; Kawazoe, A; Hashimoto, T; Kuboki, Y; Bando, H; Kojima, T; Yoshino, T; Kuwata, T; Yamaguchi, T; Nishikawa, H; Shitara, K

Corrigendum to "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer": [ESMO Open 9 (2024) 103647]

对“泛亚洲版 ESMO 胆道癌患者诊断、治疗和随访临床实践指南”的更正:[ESMO Open 9 (2024) 103647]

Chen, L-T; Vogel, A; Hsu, C; Chen, M-H; Fang, W; Pangarsa, E A; Sharma, A; Ikeda, M; Park, J O; Tan, C K; Regala, E; Tai, D; Tanasanvimon, S; Charoentum, C; Chee, C E; Lui, A; Sow, J; Oh, D-Y; Ueno, M; Ramaswamy, A; Jeo, W S; Zhou, J; Curigliano, G; Yoshino, T; Bai, L-Y; Pentheroudakis, G; Chiang, N-J; Cervantes, A; Chen, J-S; Ducreux, M

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

接受呋喹替尼联合最佳支持治疗的转移性结直肠癌患者的质量调整生存期:FRESCO-2 研究结果

Stintzing, S; Tabernero, J; Satoh, T; Dasari, A; Lonardi, S; Eng, C; Garcia-Carbonero, R; Elez, E; Yoshino, T; Sobrero, A F; Yao, J C; Kasper, S; Arnold, D; Basic, E; Granold, M; Petschulies, M; Wu, L; Chung, Y-C; Chen, L; Yang, Z; Van Cutsem, E

Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis

肿瘤和淋巴结分期对III期结肠癌患者辅助奥沙利铂化疗疗效的影响:一项ACCENT汇总分析

Cohen, R; Raeisi, M; Chibaudel, B; Yothers, G; Goldberg, R M; Bachet, J-B; Wolmark, N; Yoshino, T; Schmoll, H-J; Haller, D G; Kerr, R; Lonardi, S; George, T J; Shacham-Shmueli, E; Shi, Q; André, T; de Gramont, A

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

泛亚洲版ESMO临床实践指南,用于管理新诊断和复发性上皮性卵巢癌患者

Nag, S; Ray Coquard, I; Gupta, S; Pathak, A; Li, N; Mulya Sari, R; Harano, K; Kim, G M; Ang, S F; Que, F V; Chay, W Y; Lai, H-C; Ativitavas, T; Tangjitgamol, S; Lai, C-H; Heong, V Y M; Contreras Tolentino, J; Ngu, M R; Yun, J; Yunokawa, M; Hanafi, W L H; Li, J; Smyth, E; Yoshino, T; Mehta, J; Pentheroudakis, G; Maheshwari, A; Cervantes, A; Basade, M; Oaknin, A

Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma

晚期胃癌或胃食管交界处腺癌患者中FGFR2b表达的临床特征

Sato, S; Rhodes, S L; Aoki, Y; Nakayama, I; Hashimoto, T; Hawkins, J; Yanes, R E; Chang, C-H; Nakamura, Y; Kawazoe, A; Mishima, S; Kotani, D; Kuboki, Y; Bando, H; Kojima, T; Yoshino, S; Reading, S; Honeycutt, H; Finger, E; Endo, I; Sakamoto, N; Kuwata, T; Yoshino, T; Shitara, K

Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer

CLDN18.2阳性胃癌患者接受含佐贝妥昔单抗化疗期间早期胃炎的特征分析

Yamamoto, K; Owaki, Y; Nakayama, I; Sakamoto, N; Ishizaka, M; Kadota, T; Okemoto, D; Matsubara, Y; Miyashita, Y; Kobayashi, A; Okazaki, U; Seguchi, K; Hosokai, T; Ogura, T; Mishima, S; Kotani, D; Kawazoe, A; Hashimoto, T; Kuboki, Y; Bando, H; Kojima, T; Yoshino, T; Kuwata, T; Ishii, G; Yano, T; Shitara, K

FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer

FGFR2-IIIc亚型检测揭示了其在胃癌和胃食管交界处癌中的预后价值及其与间质转化的功能联系

Hashimoto, T; Iida, N; Kadowaki, S; Makiyama, A; Machida, N; Takahashi, N; Boku, S; Kudo, T; Oki, E; Ohtsubo, K; Kawakami, T; Okano, N; Komatsu, Y; Yuki, S; Sakamoto, N; Kuwata, T; Yamashita, R; Amisaki, M; Shibuki, T; Imai, M; Fujisawa, T; Nakamura, Y; Bando, H; Shitara, K; Yoshino, T

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer

泛亚洲版ESMO胰腺癌诊断、治疗和随访临床实践指南

Tai, D; Conroy, T; Lee, J J X; Chee, C E; Hao, C-Y; Wijaya, I; Aggarwal, S; Ueno, M; Jeung, H-C; Hashim, N M; Tan Chun Bing, J; Chen, L-T; Korphaisarn, K; Tanasanvimon, S; Chou, W-C; Cargullo, E; Muin, N F A; Lee, M A; Ohba, A; Bondarde, S; Lesmana, C R A; Wang, L; Smyth, E C; Yoshino, T; Bonney, G; Pentheroudakis, G; Samol, J; Cervantes, A; Poon, E; Ducreux, M

A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)

一项针对 BRAF V600E 突变转移性结直肠癌的艾立布林多中心 II 期研究:BRAVERY 研究 (EPOC1701)

Masuishi, T; Taniguchi, H; Kotani, D; Bando, H; Komatsu, Y; Shinozaki, E; Sunakawa, Y; Satoh, T; Nishina, T; Esaki, T; Wakabayashi, M; Nomura, S; Takahashi, K; Ono, H; Hirano, N; Fujishiro, N; Fuse, N; Sato, A; Sakamoto, Y; Kuramoto, N; Miki, I; Ichiki, H; Nakamura, Y; Sharma, G; Skrzypczak, S; Schultz, E; Kingsford, C; Ohtsu, A; Yoshino, T